Depo-Provera Meningioma Claimant Acquisition: Status and Intake

Depo-Provera is Pfizer's injectable contraceptive, depot medroxyprogesterone acetate. Women who used it for years and later developed meningiomas, tumors of the membranes around the brain and spinal cord, have sued Pfizer and generic makers in a federal MDL in the Northern District of Florida, alleging a known risk and no warning.

Intake teams should care right now because the litigation moved from a trial track to a settlement track in the summer of 2026. The question is no longer whether a case can survive to a bellwether, it is whether the claimant can register with complete proof before a reported November 30, 2026 deadline. Speed and documentation now decide who gets paid.

Where the litigation stands (September 2026)

The Judicial Panel on Multidistrict Litigation created MDL 3140 by transfer order dated February 7, 2025, sending the cases to Judge M. Casey Rodgers in the Northern District of Florida. She moved fast: a five-case pilot program in March 2025 and, by December 2025, a first bellwether, Toney v. Pfizer, set for December 7, 2026. Generic defendants Prasco, Greenstone, and Viatris were dismissed in June 2025, leaving Pfizer as the practical target.

Preemption dominated 2025. Pfizer moved for summary judgment in August 2025, arguing that the FDA had previously rejected a meningioma label change, barring state failure-to-warn claims. Judge Rodgers heard argument on September 29, 2025. Then the ground shifted: in December 2025 the FDA approved a new label warning of a potential meningioma risk and directing discontinuation if one is diagnosed. Pfizer filed a supplemental brief in February 2026 maintaining that most claims were still preempted. Pretrial Order 30, entered in January 2026 and amended in June, makes the eventual preemption and Rule 702 rulings apply to every individual action. As of September 2026, no preemption ruling has been publicly reported.

Then came settlement. On June 15, 2026, the parties notified the court of a global agreement in principle. Pfizer said it admits no liability and that the deal does not affect state court cases, mainly in New York and Delaware. Judge Rodgers vacated the December bellwether deadlines and reset the general causation hearing to July 27, 2026. Litigation reporting indicates a Master Settlement Agreement was signed July 21, 2026, that roughly 80 percent of current MDL plaintiffs are expected to be eligible, and that BrownGreer is the settlement administrator. The court's docket shows a settlement overview order on July 28, the administrator appointment on August 5, a Common Benefit Order on August 28, and September 4 orders appointing a fund administrator, an allocation master, and a lien resolution master. A case management conference and Rule 702 hearing are set for September 18, 2026. Settlement tiers, proof requirements, and dollar amounts have not been disclosed. Registration is reported to close November 30, 2026, with first payments expected in early 2027. Firms continue to file new cases.

What a qualified claimant looks like

The settlement criteria have not been released, so firms are screening to the profile the litigation has treated as strongest. Drawn from firm intake pages and litigation trackers updated in 2026, it looks like this:

• Use of Depo-Provera, Depo-SubQ Provera, or an approved generic (medroxyprogesterone acetate injection), documented in medical or pharmacy records.
• At least two injections, and many firms want a year or more of continuous use. Four or more years, and starting use after age 30, are treated as stronger.
• An imaging-confirmed diagnosis of a cranial or spinal meningioma, any WHO grade, after use began.
• Treatment matters for value: surgical resection or radiation sit in the top tiers, while surveillance-only diagnoses are accepted by some firms but valued lower.
• No prior brain tumor history.

Jurisdiction is a two-track question. Federal MDL filings fall under the settlement framework. New York and Delaware state court cases are outside it and proceed on their own schedules, so a firm needs to know about any existing filing before it promises anything.

Statute of limitations is a live problem. Most states run one to three years from diagnosis, the discovery rule is contested where the diagnosis predates the December 2025 label change, and some states have statutes of repose that close the door entirely. Get a diagnosis date and state on the first call.

Where intake goes wrong on this tort

The most common false positive is the wrong tumor. Callers say "brain tumor" and mean glioma, pituitary adenoma, acoustic neuroma, or a metastatic lesion. Only meningioma is at issue, and a screener who does not confirm the radiology or pathology wording is signing cases that will be rejected at the fact sheet stage. Related false positives: the diagnosis predates any Depo-Provera use, or the claimant took oral Provera tablets rather than the injection.

Coached claims follow the advertising. When ads run heavy on "four years or more" and "surgery," intake starts hearing exactly those answers. The tell is a claimant who reports precise long-term use but cannot name a clinic, a doctor, or a year. Ask where and when before asking how long. Duplicate claimants are a real issue because this audience has been advertised to since 2024 and many women have filled out several forms. Check for a prior retainer on every file.

Documentation is the hardest part of this tort. Depo-Provera is administered in a clinic, so proof of use lives in an OB-GYN chart, a county health department file, a family planning clinic, a college health center, or a military treatment facility, and often not in any retail pharmacy system. Providers in most states retain adult records for seven to ten years after the last visit, so use in the 2000s or early 2010s is often gone. Clinics have closed and doctors have retired. Firms are reconstructing use from insurance and Medicaid claims data, pharmacy benefit records, and the history sections of imaging and surgical reports, backed by sworn declarations. That takes weeks, and the reported registration deadline does not leave many.

Geography matters twice. Claimants in states with short limitations periods may already be out of time, and claimants who got injections at facilities that no longer exist, common in rural areas, are the ones most likely to stall on proof.

What acquisition looks like

The claimant population is women who used Depo-Provera for years, often starting in their twenties or thirties, and who are now in their forties through sixties. Many received the shot through county clinics or family planning providers rather than a private OB-GYN. Meta and connected TV perform when the creative names the drug plainly, shows the injection rather than a pill, and speaks to the symptoms that led to diagnosis: headaches, vision changes, seizures, hearing loss. News moments like the December 2025 label change and the June 2026 settlement put the drug name in front of this audience, and campaigns that run alongside them benefit.

Women remember "the shot," which makes the audience easy to reach. What makes it hard is that the meningioma diagnosis may be years old and never connected to birth control. The creative has to make that connection without overpromising.

Cost is driven by three things. Competition: this tort has been heavily advertised since 2024, and settlement news drew in more. Proof-of-use burden: the cheapest lead is worthless if the injection records cannot be found, so cost has to be measured at the documented-file stage, not the retainer stage. Timing: with a registration deadline reported for November 30, 2026, campaigns have to be paired with records retrieval from day one.

How Slingshot screens for this tort

Direct opt-in comes first. Every Depo-Provera prospect we deliver responded to our own advertising, and we hold the TCPA consent record with timestamp, source, and creative. No recycled or co-registered inventory, which matters when so many women have submitted forms to multiple advertisers. Our screening call then verifies identity against name, date of birth, and residence, and checks for prior retainers before the file moves forward.

Authentication is where this tort gets decided. We ask the claimant where and when she received injections and which facility diagnosed the meningioma. We request the imaging or pathology report that uses the word meningioma, and at least one document that places Depo-Provera use in the record: a clinic chart, a Medicaid or insurance explanation of benefits, or a pharmacy printout for the injection. A file with the diagnosis but not the use is flagged, not delivered as qualified.

Post-signature engagement keeps the file alive into records retrieval. We confirm the retainer was received, follow up on outstanding authorizations, and keep the claimant reachable for the firm's paralegal, who will need her help identifying old clinics. On a tort with a registration deadline, a claimant who goes silent for a month misses the window.

Frequently asked questions

Can law firms still sign Depo-Provera meningioma claimants after the settlement?

Yes. Firms continue to accept and file new cases as of September 2026. The June 2026 agreement covers federal MDL plaintiffs who meet criteria the parties have not published, and reporting points to a November 30, 2026 registration deadline. Claimants who do not fit the settlement, or cannot register in time, remain on a litigation track before Judge Rodgers, where preemption and Rule 702 rulings are still pending.

What proof of Depo-Provera use does a claimant need?

A record showing the drug was administered: a clinic chart, a health department or family planning record, an insurance or Medicaid claim with the relevant code, or a pharmacy record for the injection. Because the shot is given in a clinic, retail pharmacy records alone often do not exist. Firms supplement with imaging and surgical reports that note contraceptive history and with sworn declarations, but a claimant with no third-party document is a difficult case.

Does a claimant need surgery to qualify?

Public firm criteria vary. Most require an imaging-confirmed meningioma and at least two injections or a year of use, and treat surgery or radiation as a factor that raises value rather than a requirement. Some accept surveillance-only diagnoses. Settlement tiers have not been disclosed, so no one outside the parties can say how treatment history maps to eligibility or payment.

Sources

This article is published by Slingshot Legal Support, a legal marketing and claimant acquisition company. It is not legal advice and does not create an attorney-client relationship. Litigation status is described as publicly reported as of the publication date and changes frequently.